Home › Calculator › BHVN Dividend Calculator 2026
BHVN Dividend DRIP Calculator 2026
12.75% YieldHealthcareBiohaven Ltd. · NYSE
Price: $15.69 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When BHVN pays your bills
Year your monthly dividend income covers each expense (based on current settings)
Share your BHVN snowball 📈
$10,000 in BHVN → $33.2K in 10 years · $312.73/month
About Biohaven Ltd. (BHVN) — Dividend Analysis 2026
Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity. The company is also developing BHV-1510 that is in Phase 2 clinical trial for the treatment of advanced or metastatic epithelial tumors; and BHV-1530, which is in Phase 2 clinical trial for treating urothelial cancer and other tumors. In addition, its preclinical product pipeline includes BHV-1310 for treating myasthenia gravis; BHV-1320 for treating immune mediated-diseases; BHV-1450 for treating Pemphigus, MuSK MG, and LGI-1 Encephalitis; BHV-1420 for treating membranous nephropathy; BHV-1440 for treating Graves' disease and TED; BHV-6500 for treating type 1 diabetes; BHV-1490 for treating IgM neuropathy and Waldenstrom's; BHV-8100 for treating neurodegenerative diseases; and BHV-1955 for treating tinnitus. The company was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.
Compare BHVN with similar stocks
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full BHVN DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open BHVN position with:
🌍 BHVN Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold BHVN.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 12.75% | 9.95% | $1,275 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 10.84% | 8.04% | $1,084 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 10.20% | 7.40% | $1,020 / yr |
| 🇬🇧 UK ISA | 0% | 12.75% | 9.95% | $1,275 / yr |
| 🇬🇧 UK Taxable | 8.75% | 11.63% | 8.83% | $1,163 / yr |
| 🇨🇦 TFSA | 0% | 12.75% | 9.95% | $1,275 / yr |
| 🇨🇦 CA Taxable | 25% | 9.56% | 6.76% | $956 / yr |
| 🇦🇺 Super (pension) | 15% | 10.84% | 8.04% | $1,084 / yr |
| 🇦🇺 AU Taxable | 30% | 8.92% | 6.12% | $893 / yr |
| 🇩🇪 DE Taxable | 26.375% | 9.39% | 6.59% | $939 / yr |
| 🇫🇷 FR Taxable | 30% | 8.92% | 6.12% | $893 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 BHVN Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 BHVN Dividend Payment Schedule
BHVN pays quarterly — 4 times per year. Next ex-div: TBD.
📊 BHVN vs Healthcare Benchmarks
How BHVN compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for BHVN sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ BHVN Insider Activity
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| Other | 2026-07-09 | 300,000 | $7.00 | $2.10M | ||
| Other | 2026-07-09 | 78,750 | $29.49 | $2.32M | ||
| Other | 2026-07-09 | 95,250 | $41.93 | $3.99M | ||
| Other | 2026-07-09 | 83,000 | $38.64 | $3.21M | ||
| Other | 2026-07-09 | 175,000 | $11.52 | $2.02M | ||
| Other | 2026-07-09 | 14,000 | — | — | ||
| A-Award | 2026-04-28 | 68,693 | $9.61 | $660.1K | ||
| A-Award | 2026-04-28 | 68,693 | $9.61 | $660.1K | ||
| A-Award | 2026-04-28 | 68,693 | $9.61 | $660.1K | ||
| A-Award | 2026-04-28 | 68,693 | $9.61 | $660.1K |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Analyst Price Target
Wall Street consensusAnalyst consensus price target via FMP. Not a guarantee of future performance. Past analyst accuracy varies.
Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the BHVN dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Biohaven Ltd. (BHVN) is currently trading at $15.69, 70% below its 52-week high. The current dividend yield is 12.75% based on an annual payout of $2.00 per share.
BHVN (Biohaven Ltd.) — 12.75% Dividend Yield Analysis
Biohaven Ltd. (BHVN) is a healthcare stock currently trading at $15.69 with a dividend yield of 12.75%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
- Above-average yield (12.75%) may signal elevated risk — verify sustainability.
Auto-generated from live market data. For educational purposes only — not financial advice.
Latest BHVN News
LiveNews aggregated from public sources via Finnhub & RSS. For informational purposes only.